Context Therapeutics Inc. (Nasdaq: CNTX) announced its third quarter 2026 financial results and provided updates on the clinical development of its Claudin 6 x CD3 T cell engaging antibody, CTIM-76. The company reported cash and cash equivalents of $34.4 million as of September 30, 2026, a decrease from $66.0 million at the end of 2025. The company stated that this cash balance is expected to fund operations through the early fourth quarter of 2027.
Regarding CTIM-76, the company reported data from the ongoing Phase 1 trial in patients with platinum-resistant ovarian cancer (PROC). As of October 30, 2026, 27 patients had received the drug in dose escalation cohorts. Among 15 efficacy-evaluable PROC patients treated at biologically active weekly doses (140 to 280 micrograms), the confirmed objective response rate (ORR) was 22%, and the disease control rate (DCR) was 56%. The median progression-free survival (PFS) was 5.6 months.
Activity was observed across metastatic sites, including liver metastases, which are typically difficult to treat. Among four patients with liver lesions, the median reduction was 58%, with two lesions disappearing completely. The company noted that exposure increased dose-proportionally and that the pharmacokinetic profile supports evaluation of every-three-week (Q3W) dosing.
Safety data indicated that cytokine release syndrome occurred in 5 of 27 patients (18.5%), all of which were Grade 1 or 2. Grade 3 or higher treatment-emergent adverse events occurred in 22 of 27 patients (81.5%). The most common events included elevated liver enzymes, including gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT).
Context Therapeutics is currently optimizing dosing schedules. The dose-limiting toxicity evaluation period at 280 micrograms Q3W is complete, and dose escalation to 420 micrograms Q3W has begun. The company expects to initiate Phase 1b dose expansion in Q1 2027 and anticipates initial Q3W efficacy data in Q2 2027.
In other pipeline news, the company reported that the first patient was dosed in the Phase 1 trial of CT-202, a Nectin-4 x CD3 TCE, in September 2026. Six sites are active in Australia, and the company is on track to file a U.S. investigational new drug application by the end of 2026.
